Jeanmarie Guenot is a business executive in the pharmaceutical and biotechnology industry. Guenot currently serves as the President and CEO of Amphivena Therapeutics in San Francisco, CA. Guenot has vast knowledge and over 20 years of experience in dealing with cardiovascular diseases neurology, ophthalmic and autoimmune diseases, and oncology. Jeanmarie Guenot graduated from the University of California, San Francisco in 1993 with a Ph.D. and studied her MBA at the University of Pennsylvania, Wharton School. Her extensive knowledge in medicinal and physical knowledge with specialties in quantum mechanical and semi-empirical methods have seen her hold various executive positions in various companies.
LinkedIn shows us that Guenot has previously worked in different private and public companies in the pharmaceuticals, venture capitals, and business development sectors. After completion of her Ph.D. degree, Jeanmarie Guenot started her career in science at Hoffman- La Roche in 1993 as the principal scientist in Preclinical R&D. She later engaged in a business career at the Atlas Venture. At the company, she was in charge of the venture capital investment management and helped in building life science companies. Guenot was the vice president of PDL BioPharma and Managing Partner at Guenot LLC. In 2009, she founded SKS Ocular LLC, a biopharmaceutical company in San Diego, CA.
As the CEO of Amphivena Therapeutics, Guenot has led the company in developing bi-functional antibody therapies in the treatment of the hematological malignancies. The company has developed drugs such as the CD3 and the AMV-364 for the treatment of myeloid leukemia. The pharmaceutical company aims at developing drugs that restore the cellular balance in patients facing life-threatening diseases.
Significant Accomplishments at PDL BioPharma
Guenot played an important part at PDL BioPharma for the five years that she was the vice president in Business Development. Her role in the company included alliance management of profit and losses, licensing, as well as mergers and acquisitions. Guenot also licensed Ophthotech for the ophthalmic indication on the oncology drug. She contributed greatly to the co-development and co-commercialization collaboration between PDL and Biogen Idec. The $800M transaction involved three Phase 2 Cancer Patients and autoimmune drug candidates.